Stocktoria
Relay Therapeutics, Inc. RLAY
Relay Therapeutics, Inc. (RLAY) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $15.4M at a -1800.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-05-26 | Guggenheim | Buy (main) |
| 2026-05-26 | HC Wainwright & Co. | Buy (main) |
| 2026-05-20 | Barclays | Overweight (main) |
| 2026-05-20 | Citizens | Market Outperform (main) |
| 2026-05-19 | Raymond James | Strong Buy (main) |
| 2026-04-29 | HC Wainwright & Co. | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.89 |
| Retained earnings / assets | -3.243 |
| EBIT / assets | -0.487 |
| Equity / liabilities | 10.449 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| RLAY | Relay Therapeutics, Inc. | 3/9 | 2.96 | — | +53.4% |
| LCTX | Lineage Cell Therapeutics, Inc. | 3/9 | -12.25 | — | — |
| PTHS | Pelthos Therapeutics Inc. | 4/9 | -1.47 | — | — |
| ELUT | ELUTIA INC. | 4/9 | -8.05 | 0.8 | -15% |
| LENZ | LENZ Therapeutics, Inc. | 2/9 | 15.45 | — | — |
| CRBU | Caribou Biosciences, Inc. | 2/9 | -9.88 | — | — |
| ACOG | Alpha Cognition Inc. | 2/9 | 3.69 | — | — |
About Relay Therapeutics, Inc.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
FAQ
Is RLAY financially healthy?
Relay Therapeutics, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does RLAY pay a dividend?
No, Relay Therapeutics, Inc. does not currently pay a dividend.
How profitable is RLAY?
In FY2025, Relay Therapeutics, Inc. had a net margin of -1800.6% and a return on equity of -48.8%.
What is the analyst price target for RLAY?
The average Wall-Street price target for Relay Therapeutics, Inc. is $24.82, about 23.7% above the recent price, from 11 analysts (consensus: strong buy).
Is RLAY a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Relay Therapeutics, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.